(Q42743059)

English

Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia

scientific article published on 17 February 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia (English)

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Carmine Tinelli

4

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

author name string

Michela Montagna

1

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Marco Montillo

2

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Maria A Avanzini

3

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Alessandra Tedeschi

5

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Livia Visai

6

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Francesca Ricci

7

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Eleonora Vismara

8

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Enrica Morra

9

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Mario Regazzi

10

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

publication date

17 February 2011

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

96

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

6

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

932-936

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

Pharmacokinetics of alemtuzumab and the relevance in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Pharmacokinetics of CAMPATH-1H: assay development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Primary structure of CD52.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

27 May 2018

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

16 August 2018

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

16 August 2018

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

16 August 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

16 August 2018

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3105658

16 August 2018

A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application

1 reference

https://pubmed.ncbi.nlm.nih.gov/21330330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21330330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

1 reference

https://pubmed.ncbi.nlm.nih.gov/21330330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/21330330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The CAMPATH-1 antigen (CDw52)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21330330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/21330330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21330330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2010.033159

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

6 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42743059&oldid=2143724747"